We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $2.63B
1-Year Est. Return 117.41%
This Fund
S&P 500
This Quarter Est. Return
+1.77%
1 Year Est. Return
+117.41%
3 Year Est. Return
+428.82%
5 Year Est. Return
+748.21%
10 Year Est. Return
–
AUM
$1.71B
AUM Growth
+$23.5M
Cap. Flow
+$140M
Cap. Flow %
8.18%
Top 10 Hldgs %
56.71%
Holding
87
New
17
Increased
22
Reduced
12
Closed
17

Top Buys

Rank Stock Value
1
RGNX icon
Regenxbio
RGNX
+$30M
2
XNCR icon
Xencor
XNCR
+$20.4M
3
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$20M
4
GH icon
Guardant Health
GH
+$19.9M
5
TVTX icon
Travere Therapeutics
TVTX
+$17M

Top Sells

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$67.8M
2
UTHR icon
United Therapeutics
UTHR
+$18.1M
3
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$15.8M
4
ZTS icon
Zoetis
ZTS
+$14.8M
5
EXEL icon
Exelixis
EXEL
+$10.3M

Sector Composition

Rank Sector Weight
1 Healthcare 85%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PTGX icon
26
Protagonist Therapeutics
PTGX
$8.75B
$16.5M 0.96%
482,257
+184,548
+62% +$5.83M
INBX
27
DELISTED
Inhibrx, Inc. Common Stock
INBX
$16.1M 0.94%
+368,679
New +$14.7M
NXTC icon
28
NextCure
NXTC
$17.3M
$16M 0.94%
222,655
– –
GRTX
29
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
$14.2M 0.83%
3,083,712
– –
INZY
30
DELISTED
Inozyme Pharma
INZY
$13.8M 0.81%
2,028,308
– –
IMTX icon
31
Immatics
IMTX
$1.24B
$13.8M 0.81%
1,026,623
+548,407
+115% +$6.85M
BOLT icon
32
Bolt Biotherapeutics
BOLT
$7.36M
$13.5M 0.79%
137,722
– –
ISEE
33
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$13.4M 0.78%
798,789
+441,389
+124% +$7.23M
NCNA
34
NuCana
NCNA
$5.37M
$13.3M 0.78%
1,120
– –
JNCE
35
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$13.2M 0.77%
1,582,777
+945,430
+148% +$7.79M
IMGN
36
DELISTED
Immunogen Inc
IMGN
$13M 0.76%
+1,749,882
New +$10.9M
AKUS
37
DELISTED
Akouos Inc
AKUS
$12.9M 0.75%
1,515,074
– –
INSM icon
38
Insmed
INSM
$23.2B
$12M 0.7%
441,773
-93,347
-17% -$2.67M
FULC icon
39
Fulcrum Therapeutics
FULC
$248M
$10.9M 0.64%
617,670
+566,664
+1,111% +$11.2M
SRPT icon
40
Sarepta Therapeutics
SRPT
$1.66B
$10.9M 0.64%
120,732
-36,547
-23% -$3.12M
CLDX icon
41
Celldex Therapeutics
CLDX
$2.77B
$10.5M 0.61%
271,533
+134,501
+98% +$5.86M
CMPI
42
DELISTED
Checkmate Pharmaceuticals, Inc. Common Stock
CMPI
$10.4M 0.6%
3,606,707
– –
PTGX icon
43
CALL
Protagonist Therapeutics
PTGX
$8.75B
$10.3M 0.6%
300,600
+600
+0.2% +$19K
QURE icon
44
uniQure
QURE
$2.68B
$10.3M 0.6%
495,025
+416,283
+529% +$11.9M
OBSV
45
DELISTED
ObsEva SA Ordinary Shares
OBSV
$9.45M 0.55%
4,749,623
– –
VIR icon
46
PUT
Vir Biotechnology
VIR
$1.47B
$8.37M 0.49%
+200,000
New +$7.84M
BMRN icon
47
BioMarin Pharmaceuticals
BMRN
$11.5B
$7.71M 0.45%
+87,322
New +$7.21M
ZYME icon
48
Zymeworks
ZYME
$1.68B
$6.44M 0.38%
392,712
-17,907
-4% -$373K
AGEN
49
Agenus
AGEN
$249M
$6.32M 0.37%
99,915
-19,533
-16% -$1.54M
IFRX icon
50
InflaRx
IFRX
$256M
$5.53M 0.32%
+1,161,736
New +$4.67M
1
2
3 4

Similar funds

WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $2.63B AUM 20.53% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
WCA
Waratah Capital Advisors Toronto, Ontario, Canada $2.63B AUM 76.33% 1-Year Est. Return
ACM
Advance Capital Management Southfield, Michigan $2.64B AUM 13.57% 1-Year Est. Return
NIG
NFJ Investment Group Dallas, Texas $2.64B AUM 23.86% 1-Year Est. Return
WBG
Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Sofinnova Investments's Q4 2021 Portfolio in Review

As of Q4 2021, Sofinnova Investments held 87 positions worth $1.71B, up 1.4% from $1.69B the previous quarter. Its ten largest holdings account for 57% of the portfolio.

Sofinnova Investments deployed $140M of net new capital in Q4 2021, opening 17 new positions and adding to 22 existing holdings. Its largest new stake was Xencor: 537,030 shares worth $21.5M.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, down from 91% a quarter earlier.

On the sell side, the largest reduction was United Therapeutics, an estimated $18.1M trimmed.

  • Sofinnova Investments's largest Q4 2021 buy was Xencor: 537,030 shares worth $21.5M.
  • Sofinnova Investments added most to Regenxbio in Q4 2021, an estimated $30M increase.
  • Sofinnova Investments's biggest Q4 2021 reduction was United Therapeutics, cutting an estimated $18.1M.
  • Sofinnova Investments fully exited AstraZeneca in Q4 2021, selling an estimated $67.8M.
  • Sofinnova Investments's ten largest holdings make up 57% of its $1.71B portfolio in Q4 2021.
  • Sofinnova Investments opened 17 new positions and closed 17 in Q4 2021.
  • Sofinnova Investments's portfolio value rose 1.4% quarter-over-quarter to $1.71B.

Based on Sofinnova Investments's 13F filing for Q4 2021, filed 14 Feb 2022.